SAB Biotherapeutics Strengthens Board of Directors with Appointment of Biotech Veteran
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, today announced that Thorkil Kastberg Christensen has joined their Board of Directors. SAB, which was founded in 2014, develops human antibody therapeutics using its first-of-its-kind immunotherapy platform.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170426006134/en/
Thorkil Kastberg Christensen (Photo provided by Thorkil K. Christensen)
Christensen brings to SAB decades of global business strategy and execution as former Chief Financial Officer of Denmark-based Novo A/S, which invests and manages the assets of the Novo Nordisk Foundation valued at about US$40 billion. He also established Novo Nordisk organizations around the world over two decades–as CEO of China and Vice President of International Operations.
“SAB’s technology is a platform for development of better and more effective medicines in many areas with unmet needs,” said Thorkil Kastberg Christensen. “This is at the heart of what I have been doing most of my life and I am happy to be able contribute,” he added.
Currently, Christensen serves as advisor for Novo A/S and a professional board member for Strategic Design Group and Sonion A/S among others. Since 2009, he has held additional board positions with private and publicly listed companies, in Denmark, abroad, and in public institutions including Chairman of the board of Danish-Chinese Business Forum, Jørgen Kruuse A/S and BioMimetics Inc., USA.
For SAB, Christensen has served as a strategic international business advisor since July of 2015.
“Mr. Christensen has been a trusted advisor and asset to SAB as we have advanced our technology and expanded collaborations within the U.S. and globally,” said Eddie Sullivan, Ph.D., president and CEO of SAB Biotherapeutics.
“His experience with financing, technology deployment and his network with leading public health, biotech and Pharma organizations will be valuable to the board as we continue to build our footprint and portfolio,” he added.
As a proven leader in life science business, Christensen has specialized in internationalization, as well as mergers, acquisitions, and other transactions. This work includes building organizations, transforming companies from R&D to commercial focus, and adding value to growing companies.
“The possibilities for using human antibodies, and polyclonals in particular, for the benefit of mankind are endless and in many areas there are great commercial potentials as well,” said Christensen. “I look forward to working closer with the colleagues at SAB in striving to realize some of these potentials.”
SAB is developing products for several targets including seasonal influenza, mycoplasma, C-Diff, Zika and Ebola. In addition, a Phase I Clinical Trial with the National Institutes of Health for its treatment for MERS-CoV is nearly complete and has funding support from BARDA for Phase 2.
In 2016 SAB’s novel immunotherapy platform was recognized by the World Health Organization as the most promising therapeutic platform technology to combat priority pathogens as well as other diseases with epidemic potential.
“With the unique capability of our technology platform in its ability to rapidly respond to various life-threatening diseases, our business is a global one,” added Sullivan. “Leveraging Mr. Christensen’s experience and expertise will only strengthen our capability to bring life-saving therapies to people in countries around the world.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical stage, biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced polyclonal antibody science in the world, SAB is delivering the world’s first large-scale platform to create fully human immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
SAB Biotherapeutics, Inc.
Melissa Ullerich, +1 605-695-8350
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Meet Group Announces Closing of Lovoo Acquisition19.10.2017 20:58 | Pressemelding
The Meet Group, Inc. (NASDAQ: MEET), a public market leader in the mobile meeting space, has completed its acquisition of Lovoo GmbH. The LOVOO app is the most downloaded dating app in Germany, Switzerland, and Austria combined. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171019006572/en/ The Meet Group anticipates this purchase will continue the momentum of its mission to meet the universal need for human connection through innovating, acquiring, and building the largest mobile portfolio of brands for meeting new people. The acquisition is expected to expand The Meet Group’s global footprint, increase the company’s scale and profitability, and diversify its business model by adding expertise in subscription and in-app purchasing. “LOVOO is our third strategic acquisition in the last 12 months, and
Edgewater Networks Announces SD-WAN Optimized for BroadSoft Platforms19.10.2017 20:00 | Pressemelding
Edgewater Networks, Inc., the market leader in Network Edge Orchestration, announces the upcoming availability of its SD-WAN offering targeted for Small to Medium Enterprises, a key market for service providers offering Unified Communications as a Service. Edgewater Networks’ SD-WAN solution is optimized for the BroadSoft BroadWorks® and BroadCloud® platforms and brings the benefits of this technology to the BroadSoft customer base. “As a new component of our Network Edge Orchestration platform, Edgewater Networks SD-WAN service allows BroadSoft customers to offer comprehensive end user service level agreements by ensuring that real-time communications are automatically routed to the best available Internet connection,” said Chris Kolstad, Edgewater Networks’ Vice President of Product Management. “Edgewater Networks’ SD-WAN offers a new revenue stream to service providers with a soluti
Business Wire Receives Type 2 SOC 2 Attestation Engagement Report Related to Security19.10.2017 19:20 | Pressemelding
Business Wire today announced that it has successfully completed a Type 2 SOC 2 examination of its BW Connect and HQ systems. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171019006400/en/ The attestation engagement report, conducted by the independent CPA firm Schellman & Company, LLC, confirms that Business Wire has met the standards established by the American Institute of Certified Public Accountants [AICPA] Trust Services Principles related to security. BW Connect is Business Wire’s proprietary web-based order-entry system; HQ provides web-hosting services for online newsrooms, and investor relations hubs for publicly-traded companies. The examination, conducted during the review period February 1, 2017 through July 31, 2017, focused on Business Wire adherence to the Trust Service Principle/Secu
Pharnext: First-Half 201719.10.2017 17:30 | Pressemelding
Regulatory News: Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced its first-half 2017 financial results. Daniel Cohen, M.D., Ph.D. Co-Founder and CEO said of activity for the first half of 2017: "Activity in the first-half of the year was very dense; we implemented two prominent strategic partnerships with the biotech company Galapagos and the Tasly Group, one of the top ten pharmaceutical companies in China. Our flagship product, PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A, is nearing the end of Phase 3, which is slated for the second half of 2018. We confirm our target of taking the product to market by 2019." A half-year marked by strategic agreements
Tickets Now on Sale for FEI World Equestrian Games Tryon 2018, North Carolina, USA, on September 11-23, 201819.10.2017 16:58 | Pressemelding
Tickets for the FEI World Equestrian GamesTM Tryon 2018 (WEG) are now on sale to the public online at www.tryon2018.com. With more than 500,000 people expected to attend the 2018 Games, the 12-day spectacle of equestrian champions is one of the biggest events on the global sporting calendar and will be the largest equestrian event in North Carolina’s history. Mark Bellissimo, CEO of host venue Tryon International Equestrian Center (TIEC) in Tryon, NC, USA, said: “Demand from the event is way beyond our expectations and it would not surprise me if this event were to sell out early. We have experienced unprecedented demand, far bigger than we ever anticipated. There is tremendous appetite for this event, so we encourage people to buy now.” Tickets for the WEG include the following options: a standard Day Pass, Individual Event Pass, All Session Discipline Pas
SFL – Third-Quarter 2017 Financial Information19.10.2017 16:30 | Pressemelding
Regulatory News: SFL (Paris:FLY): Rental income: €147.8 million, up 3.3% like-for-like Consolidated revenue by business segment (€000’s) 2017 (9 months) 2016 (9 months)
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom